Earnings Releases·Oct 29, 2026, 8:25 AM ET

Establishment Labs — Third Quarter 2026 Earnings Summary

Total revenue reached $72.0 million, a 33.9% year-over-year increase driven by a 119.0% surge in U.S. sales, while GAAP net loss narrowed to $10.7 million and adjusted EBITDA rose to $6.4 million.
The company achieved its first-ever positive quarter for operating and free cash flow ($5.1 million), supported by a 70.8% adjusted gross margin and expanded U.S. commercial footprint to over 2,100 accounts.
Full-year 2026 revenue guidance was raised to over $274 million, with management projecting positive adjusted EBITDA for the year and 25% growth with positive cash flow in fiscal 2027.
Strategic milestones include FDA approval for additional Motiva implant sizes, a new manufacturing supply agreement with NuSil, and ongoing FDA review for Motiva breast reconstruction.